Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC)

被引：0
|
作者：
Morris, M. [1 ]
Vogelzang, N. J. [2 ]
Sartor, O. [3 ]
Armour, A. [4 ]
Groaning, M. [5 ]
Messmann, R. [6 ]
Robarts, A. [7 ]
Petrylak, D. P. [8 ]
Tolcher, A. [9 ]
Gordon, M. S. [10 ]
Babiker, H. [11 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, 1275 York Ave, New York, NY 10021 USA
[2] Comprehens Canc Ctr Nevada, Med Oncol, Las Vegas, NV USA
[3] Tulane Univ, Oncol, New Orleans, LA 70118 USA
[4] Endocyte Inc, Med, Indianapolis, IN USA
[5] Endocyte, Clin, Indianapolis, IN USA
[6] Endocyte, Med Oncol, W Lafayette, IN USA
[7] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, 1275 York Ave, New York, NY 10021 USA
[8] Yale Univ, Sch Med, Med Oncol, New Haven, CT USA
[9] START, Med Oncol, San Antonio, TX USA
[10] HonorHlth Res Inst, Med Oncol, Scottsdale, AZ USA
[11] Univ Arizona, Ctr Comprehens Canc, Med Oncol, Tucson, AZ USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
793PD
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase II Trial of Sipuleucel-T and Stereotactic Ablative Radiation therapy (SAbR) for Patients with Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
    Dohopolski, M.
    Watumull, L.
    Mathews, D.
    Gao, A.
    Garant, A.
    Choy, H.
    Ahn, C.
    Timmerman, R. D.
    Courtney, K.
    Hannan, R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E879 - E879
  • [42] A phase I study of the multikinase inhibitor cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC)
    Karzai, Fatima H.
    Shah, Avani Atul
    Ojemuyiwa, Michelle A.
    Madan, Ravi Amrit
    Apolo, Andrea Borghese
    Dawson, Nancy Ann
    Arlen, Philip M.
    Theoret, Marc Robert
    Wright, John Joseph
    Chen, Clara
    Trepel, Jane B.
    Couvillon, Anna
    Chun, Guinevere
    Harold, Nancy
    Steinberg, Seth M.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [43] Phase I study of CCW702, a bispecific small molecule-antibody conjugate targeting PSMA and CD3 in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Markowski, Mark Christopher
    Kilari, Deepak
    Eisenberger, Mario A.
    Mckay, Rana R.
    Dreicer, Robert
    Trikha, Mohit
    Heath, Elisabeth I.
    Li, Jing
    Garzone, Pamela D.
    Young, Travis S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [44] Ipilimumab (IPI) in metastatic castrate-resistant prostate cancer (mCRPC): Results from an open-label, multicenter phase I/II study
    Slovin, Susan F.
    Hamid, Omid
    Tejwani, Sheela
    Higano, Celestia S.
    Harzstark, Andrea
    Alumkal, Joshi J.
    Scher, Howard I.
    Chin, Kevin M.
    Gagnier, Paul
    McHenry, M. Brent
    Beer, Tomasz M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [45] Advances in non-radioactive PSMA-targeted small molecule-drug conjugates in the treatment of prostate cancer
    Chen, Min
    Cai, Linxuan
    Xiang, Yu
    Zhong, Ling
    Shi, Jianyou
    BIOORGANIC CHEMISTRY, 2023, 141
  • [46] Small-molecule inhibitors targeting a specific metabolic pathway for precision therapy of advanced castrate-resistant prostate cancer.
    Basu, Hirak
    Wilganowski, Nathaniel
    Lieblich, Jessica
    Wu, Grace
    Fokt, Izabela
    Ramachandran, Sumankalai
    Yu, Jiaquin
    Titus, Mark
    Priebe, Waldemar
    Beebe, David J.
    Wilding, George
    CANCER RESEARCH, 2018, 78 (16) : 128 - 128
  • [47] Treatment outcomes for metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) following docetaxel (D) for hormone sensitive disease
    Schmidt, Andrew Lachlan
    Anton, Angelyn
    Wong, Shirley S.
    Azad, Arun
    Kwan, Edmond Michael
    Spain, Lavinia Anne
    Torres, Javier
    Muthusamy, Arunbalaji
    Parente, Phillip
    Parnis, Francis
    Goh, Jeffrey C.
    Joshua, Anthony M.
    Pook, David William
    Gibbs, Peter
    Tran, Ben
    Weickhardt, Andrew James
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [48] Prevalence of ARV7 in Asian metastatic castrate-resistant prostate cancer (mCRPC) patients using multiple detection platforms
    Chan, Johan
    Ong, Whee Sze
    Ng, Quan Sing
    Toh, Chee-Keong
    Rajasekaran, Tanujaa
    Tan, Wan Ling
    Tan, Hui Shan
    Tan, Min-Han
    Lim, Kiat Hon
    Lee, Yifang
    Wong, Siew Wei
    Wong, Alvin S. C.
    Saad, Marniza Bte
    Ng, Chi-Fai
    Chansriwong, Phichai
    Horie, Shigeo
    Kanesvaran, Ravindran
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [49] Characteristics and outcome of octogenarian versus young patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) treated with ketoconazole.
    Sinibaldi, Victoria J.
    Dadon-Nachum, Michal
    Gottfried, Maya
    Maimon, Natalie
    Dovrish, Zamir
    Peer, Avivit
    Neumann, Avivit
    Sella, Avishay
    Kovel, Svetlana
    Carducci, Michael Anthony
    Eisenberger, Mario A.
    Kejzman, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [50] Lutetium-177 labelled prostate-specific membrane antigen (PSMA) for metastatic castrate-resistant prostate cancer (MCRPC): a systematic review and meta-analysis
    Calopedos, R.
    Chalasani, V.
    Asher, R.
    Emmett, L.
    Woo, H.
    INTERNATIONAL JOURNAL OF UROLOGY, 2017, 24 : 110 - 110
12345